Navigation Links
CISBIO Bioassays Launches Chromoa(TM) Chromogranin A ELISA Kit
Date:9/23/2008

Company's Expertise in Chromogranin A Tumor Detection Marker Technology Now

Applied to Universal Technique

BAGNOLS-SUR-CEZE, France, September 23 /PRNewswire/ -- CISBIO Bioassays, a member of IBA group and a developer and marketer of diagnostic assays for the quantification of tumor markers, announced today the launch of its chromogranin A ELISA diagnostic tool, Chromoa. This ELISA kit complements CISBIO's existing chromogranin A RIACT kit and can be used by all laboratories for the detection and monitoring of neuroendocrine tumors.

Chromoa is a highly-sensitive, monoclonal antibody-based assay used to identify increased protein levels in serum when a neuroendocrine tumor is present in the human body. The most common neuroendocrine tumors affect the adrenal gland, the pancreas and the digestive track. Chromogranin A (CgA) is an increasingly essential analyte for the detection and monitoring of these tumors as well as prostate cancer, which can evolve into an aggressive, neuroendocrine form.

CGA-RIACT has long been part of CISBIO'S tumor markers detection portfolio and its analytical and clinical performance has been documented in scientific publications for over a decade. Based on the same monoclonal antibody as CGA-RIACT, Chromoa offers the same reliable results but in an ELISA format. This new kit features a longer shelf life and offers easier stock management for technicians, making it a convenient, time and cost saving alternative. Particularly suitable for laboratories that do not use radioactive kits, enzyme-linked immunosorbent assays (ELISA) have been used for the quantitative analysis of protein blood samples for two decades and can be adopted by any laboratory.

Chromoa is marketed worldwide by CISBIO and its distribution network. In the U.S., the kit is available for research use only.

About CISBIO Bioassays

CISBIO Bioassays develops, manufactures and markets diagnostic assays for the quantification of tumor markers and other biomarkers in clinical biology. In addition, CISBIO is a global developer of products and technologies that are used in assay development for drug screening procedures and produces a selection of biological reagents and methods used by pharmaceutical and biotechnology companies and contract research organizations (CROs). Headquartered in Bagnols-sur-Ceze, France, CISBIO is a member of the IBA group. IBA develops and markets leading edge technologies, pharmaceuticals and tailor-made solutions for healthcare with a focus on cancer diagnosis and therapy. Leveraging its scientific expertise, IBA is also active in the field of industrial sterilization and ionization. Listed on the pan-European stock exchange EURONEXT, IBA is included in the BelMid Index. For more information about CISBIO and IBA: http://www.iba-worldwide.com.

Chromoa(TM) is a trademark of CISBIO Bioassays.


'/>"/>
SOURCE CISBIO Bioassays
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Cyntellect Launches CellXpress(TM) System to Boost Productivity of Biopharmaceutical Process Development
2. Histogen Launches BioNuesis, the Only All-Human Stem Cell Culturing Kit
3. Sigma-Aldrich Launches Breakthrough Genome-Editing Tools
4. Lena Chow, Veteran Biotech Marketer, Launches New Website
5. BioSpace Launches Life Science Career Content and Resources from the Biotech Work Portal
6. Sinovac Launches Seasonal Influenza Vaccine Anflu(R) for 2008-2009 Flu Season
7. Caliper Launches Small Animal Molecular Imaging System Enabling Real-Time Video Observation
8. SACHEM Launches 2-D HPLC e-Learning Program : New e-Learning Program Teaches Scientists How to Better Analyze and Prove Product Purity Through Greater Sensitivity and Precision in Identification of Trace Components
9. Familybuilder Launches the Familybuilder Global Network at DEMOfall 08
10. SearchMedica Launches Practice Management Search Engine for Medical Professionals
11. BIOLOCK(TM) USA Launches Affordable Fingerprint door Locks for Homes and Offices
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... Singh Biotechnology today announced that ... SBT-100, its novel anti-STAT3 (Signal Transducer and Activator of Transcription 3) B VHH13 ... cross the cell membrane and bind intracellular STAT3 and inhibit its function. Dysregulation ...
(Date:10/10/2017)... CA (PRWEB) , ... October ... ... a development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, today ... of targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in collaboration ...
(Date:10/10/2017)... California (PRWEB) , ... October 10, 2017 , ... Dr. ... speaking at his local San Diego Rotary Club. The event entitled ... Diego, CA and had 300+ attendees. Dr. Harman, DVM, MPVM was joined by ...
(Date:10/10/2017)... , Oct. 10, 2017 SomaGenics announced ... the NIH to develop RealSeq®-SC (Single Cell), expected to ... profiling small RNAs (including microRNAs) from single cells using ... highlights the need to accelerate development of approaches to ... "New techniques for measuring levels of ...
Breaking Biology Technology:
(Date:4/24/2017)... Janice Kephart , former 9/11 ... Partners, LLP (IdSP) , today issues the following ... March 6, 2017 Executive Order: Protecting the ... be instilled with greater confidence, enabling the reactivation ... applications are suspended by until at least July ...
(Date:4/13/2017)... According to a new market research report "Consumer ... Administration, and Authorization), Service, Authentication Type, Deployment Mode, Vertical, and Region - ... to grow from USD 14.30 Billion in 2017 to USD 31.75 Billion ... ... MarketsandMarkets Logo ...
(Date:4/6/2017)... 6, 2017 Forecasts by Product ... Readers, by End-Use (Transportation & Logistics, Government & Public ... & Fossil Generation Facility, Nuclear Power), Industrial, Retail, Business ... Are you looking for a definitive report on ... ...
Breaking Biology News(10 mins):